SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending due to a contentious short report from Muddy Waters, which has triggered heavy selling volume and intense debate among retail investors. The community remains deeply divided, with many traders dismissing the report as a coordinated "short and distort" tactic to facilitate short covering, while others express growing concern over the potential impact of the allegations on management's credibility.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is seeing intense investor focus fueled by a flurry of strategic acquisitions, including Rotron Aerospace and 4M Defense, alongside a high-profile partnership with Palantir that has bolstered its status as an emerging defense prime. While the stock experiences significant intraday volatility and selling pressure attributed to warrant-related hedging, the community remains heavily bullish, fixated on the upcoming earnings report and the company's potential to secure major government defense contracts in an increasingly autonomous and drone-centric global threat landscape.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is experiencing extreme volatility driven by a massive insider share purchase by the CEO and growing investor anticipation regarding a potential partnership with OpenAI. The community remains deeply divided, with some traders viewing these catalysts as a long-term bottoming signal, while others criticize the company's executive compensation and struggle to reconcile the positive news with the stock's persistent intraday sell-offs.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as the community highlights recent long-term clinical data showing Briumvi's high efficacy and record-low relapse rates, fueling speculation about potential buyouts or increased market share. Investors are actively discussing the stock's growth potential versus its current price suppression, while closely watching for upcoming earnings and subcutaneous treatment updates.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is experiencing a volatile and high-momentum market debut as investors speculate on its drone autonomy software, which has gained attention for its reported real-world combat application. The community remains sharply divided, with some betting on a parabolic "low-float" squeeze driven by defense industry demand, while others caution against potential hype-driven instability and speculative valuations.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is facing heightened volatility as traders weigh strong product milestones in AI data center infrastructure against recent insider selling and broader market rotation out of high-growth semiconductor plays. The community is actively debating the stock's future, with many interpreting recent sharp price swings as manipulative shakeouts while bulls focus on the company's long-term potential in AI connectivity.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors weigh strong demand for its GLP-1 franchise against intense market competition and analyst downgrades regarding valuation and addressable market size. The community remains highly focused on the company's upcoming pipeline catalysts, specifically the anticipated approval of its oral weight-loss drug, while debating whether recent share price volatility represents a buying opportunity or a correction from previous overvaluation.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the following segments: B&W Renewable, B&W Environmental, and B&W Thermal. The B&W Renewable segment supports a circular economy, diverting waste from landfills to use for power generation and replacing fossil fuels, while recovering metals and reducing emissions. The B&W Environmental segment focuses on systems for cooling, ash handling, particulate control, nitrogen oxides and sulfur dioxides removal, chemical looping for carbon control, and mercury control. The B&W Thermal segment offers steam generation equipment, aftermarket parts, construction, maintenance, and field services for plants in the power generation, oil and gas, and industrial sectors. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox is trending as investors digest a major $2.4 billion contract to provide 1.2 gigawatts of power generation for AI data centers, a deal widely viewed as a transformational catalyst for the company. The community is actively discussing the stock's role in the AI infrastructure and power generation sector, with many dismissing recent short-seller reports as manipulation and focusing instead on a strong project pipeline and potential for significant long-term growth.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is experiencing high volatility as investors weigh milestone euphoria, including recent NRC licensing wins and DOE design agreements, against earnings anxiety ahead of the company's financial report. While community sentiment is polarized between long-term optimism about Oklo's role in powering AI data centers and skepticism over its pre-revenue status, the stock remains a focal point for momentum traders watching closely for potential business updates.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending following a massive $27 billion AI infrastructure deal with Meta, which effectively cements its status as a leading hyperscaler. While the stock initially surged, it faced downward pressure due to the announcement of a $3.75 billion convertible senior notes offering, sparking intense debate among investors over whether the move represents necessary capital-intensive growth or dilutive overreach.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in Sanofi (NASDAQ:SNY) Declines By 17.4%

Sanofi (NASDAQ:SNY - Get Free Report) saw a significant drop in short interest in the month of February. As of February 27th, there was short interest totaling 6,560,718 shares, a drop of 17.4% from...

CSM Advisors LLC Acquires Shares of 386,534 Sanofi $SNY

CSM Advisors LLC bought a new stake in Sanofi (NASDAQ:SNY - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission...

XY Capital Ltd Acquires Shares of 33,970 Sanofi $SNY

XY Capital Ltd bought a new position in Sanofi (NASDAQ:SNY - Free Report) during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 33,970 shares...

Van ECK Associates Corp Sells 36,682 Shares of Sanofi $SNY

Van ECK Associates Corp reduced its holdings in Sanofi (NASDAQ:SNY - Free Report) by 5.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission...

SageView Advisory Group LLC Makes New Investment in Sanofi $SNY

SageView Advisory Group LLC bought a new stake in shares of Sanofi (NASDAQ:SNY - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange...

Barrow Hanley Mewhinney & Strauss LLC Lowers Holdings in Sanofi $SNY

Barrow Hanley Mewhinney & Strauss LLC lowered its position in Sanofi (NASDAQ:SNY - Free Report) by 2.1% during the 3rd quarter, according to the company in its most recent disclosure with the...

Grantham Mayo Van Otterloo & Co. LLC Buys 42,491 Shares of Sanofi $SNY

Grantham Mayo Van Otterloo & Co. LLC raised its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 99.6% during the 3rd quarter, according to the company in its most recent 13F filing with the...

<ul class="summary-bullets"><li>The “go” decision was reached early, ahead of the company’s second quarter expected timeline.</li><li>The results from the interim analysis appear stronger than those reported by Sanofi's experimental drug riliprubart in its open-label mid-stage CIDP study, Truist said.</li><li>H.C. Wainwright increased its view of the probability of launch for claseprubart to 35% from a previous 26%.</li></ul>Shares of Dianthus Therapeutics, Inc. (DNTH) soared 19% on Monday after the company announced an early “go” decision for its experimental drug claseprubart in its Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) program, boosting Wall Street optimism.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-early-go-decision-following">said</a> that the decision was based on an analysis of data from a part of its late-stage trial in which a response rate of 50% or greater was observed. Twenty or more responders were confirmed out of the first 40 participants to complete part A of the trial and no related serious infections or discontinuations were observed, the company said.The “go” decision was reached early, ahead of the company’s second quarter expected timeline, and confirmed by an independent Data Safety Monitoring Board review, it added.The decision supports continued development of claseprubart into the pivotal portion of the trial in CIDP, the company said. Dianthus Therapeutics said that it will maintain the dose as is in the part A portion of the trial and engage with regulators to remove a lower dose arm in the part B portion.Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare, acquired autoimmune disorder where the immune system damages the myelin sheath of peripheral nerves, causing progressive or relapsing muscle weakness, numbness, and sensory loss. Other firms developing drugs for the condition include Sanofi (SNY) and Argenx SE (ARGX).<h2 class="st-heading-2">Wall Street Responds</h2>Truist raised the firm's price target on Dianthus to $110 from $63 and kept a ‘Buy’ rating on the shares. The results from the interim analysis appear stronger than those reported by Sanofi's experimental drug riliprubart in its open-label mid-stage CIDP study, the analyst told investors in a research note.H.C. Wainwright analyst Swayampakula Ramakanth, meanwhile, raised the firm's price target on Dianthus to $130 from $47 and kept a ‘Buy’ rating on the shares. The firm increased its view of the probability of launch for claseprubart to 35% from a previous 26% and also raised its price estimate to $450,000 per patient per annum compared to its prior $250,000 estimate.TD Cowen, which views Dianthus as "a viable takeout target," also kept a ‘Buy’ rating on the shares.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around DNTH stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/DNTH">DNTH stock</a> has more than tripled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/jim-cramer-terrific-ai-stock-pick-gev-gets-double-upgrade/cZdVrjXRIIw">Jim Cramer's 'Terrific' AI Stock Pick Is Already Up 26% YTD, And It Just Received A Double Upgrade Today — Here's Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Dianthus Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch

Dianthus Therapeutics announced an early “go” decision for its experimental drug claseprubart in its Chronic Inflammatory Demyelinating Polyneuropathy program based on analysis of data from a part of its late-stage trial. 

Equity

Will Weak Gardasil Sales Continue to Weigh on MRK's Top Line in 2026?

Merck faces continued pressure as Gardasil sales slump 39% in 2025, hit by weak China demand, with management expecting no rebound in 2026.

FY2026 EPS Estimates for Sanofi Reduced by Erste Group Bank

Sanofi (NASDAQ:SNY - Free Report) - Investment analysts at Erste Group Bank dropped their FY2026 earnings estimates for shares of Sanofi in a report released on Wednesday, March 4th. Erste Group Bank...

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$1.05	--	--	N/A
Q4 '25	$0.84	$0.91	8.38%	BEAT
Q3 '25	$1.58	$1.69	7.23%	BEAT
Q2 '25	$0.96	$0.91	-5.11%	MISSED
Q1 '25	$0.93	$0.78	-15.53%	MISSED

SNY
Sanofi-Aventis

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest SNY News

SNYSanofi-Aventis